These drugs target GLP-1R, and their use in neuroendocrine cancer patients with medullary thyroid carcinoma (thyroid NET) or multiple endocrine neoplasia syndrome type 2 is deemed contraindicated. The gene discussed is GLP1R; the disease is neuroendocrine carcinoma.